Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial-Reference-Cited by-同舟云学术

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

Published:2016-03 Issue:3 Volume:17 Page:319-331
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Trněný Marek,Lamy Thierry,Walewski Jan,Belada David,Mayer Jiri,Radford John,Jurczak Wojciech,Morschhauser Franck,Alexeeva Julia,Rule Simon,Afanasyev Boris,Kaplanov Kamil,Thyss Antoine,Kuzmin Alexej,Voloshin Sergey,Kuliczkowski Kazimierz,Giza Agnieszka,Milpied Noel,Stelitano Caterina,Marks Reinhard,Trümper Lorenz,Biyukov Tsvetan,Patturajan Meera,Bravo Marie-Laure Casadebaig,Arcaini Luca

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. The Non-Hodgkin's Lymphoma Classification Project;Blood,1997

2. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004;Zhou;Cancer,2008

3. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project;Armitage;J Clin Oncol,1998

4. Mantle cell lymphoma: the promise of new treatment options;Goy;Crit Rev Oncol Hematol,2011

5. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol,2014

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma;BLOOD ADV;2024

2. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma;Blood Advances;2024-07-11

3. Targeted Therapies in the Treatment of Mantle Cell Lymphoma;Cancers;2024-05-20

4. Management of relapsed/refractory mantle cell lymphoma;Leukemia & Lymphoma;2024-04-18

5. Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma;Discover Oncology;2024-04-05